Ischemic stroke in patients with atrial fibrillation is associated with substantial morbidity and
mortality. The growing epidemic of atrial fibrillation worldwide has raised concerns about the …

Objectives To assess cost-effectiveness of direct oral anticoagulants (DOACs) compared
with vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF) by pooling …

Aims Previous studies on the cost-effectiveness of screening for atrial fibrillation (AF) are
based on assumptions of long-term clinical effects. The STROKESTOP study, which …

What is known and objective With the high cost, the long‐term persistence of new oral
anticoagulants (NOACs) was lower than that of warfarin in Chinese patients with non …

Introduction Economic evaluations are becoming increasingly important due to limitations in
economic resources, the expense of many new treatments, the need to allocate health …

ABSTRACT Background and Objectives: Rivaroxaban is noninferior to warfarin for
preventing stroke or systemic embolism in patients with high-risk atrial fibrillation (AF) and is …

The introduction of non-vitamin K antagonist oral anticoagulants (NOACs) into clinical
practice represented a major change in the treatment of non-valvular atrial fibrillation …

Background Strokes attributed to atrial fibrillation (AF) represent a major cause of adult
disability and a great burden to society and healthcare systems. Objectives Our objective …

Background Long-term oral anticoagulant treatment is obligatory in patients with atrial
fibrillation (AF, score of CHA 2 DS 2 VASc≥ 2). When these patients undergo percutaneous …

A budget impact analysis estimates the short-term difference between the cost of the current
treatment strategy and a new treatment strategy, in this case to implement population …